Skip to main content
Antoinette Tan, MD, Oncology, Charlotte, NC, Atrium Health's Carolinas Medical Center

AntoinetteRoslynTanMDMHSc

Oncology Charlotte, NC

Breast Cancer

Chief, Section of Breast Medical Oncology, Levine Cancer Institute, Atrium Health Chair, Department of Solid Tumor and Investigational Therapeutics, Levine Cancer Institute, Atrium Health

Dr. Tan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tan's full profile

Already have an account?

Summary

  • Dr. Antoinette Tan is an oncologist in Charlotte, NC and is affiliated with Atrium Health's Levine Cancer Institute. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 23 years. She specializes in breast cancer and is experienced in breast cancer and medical oncology. She has more than 80 publications and over 500 citings.

Education & Training

  • Duke University
    Duke UniversityMHSc, Clinical Research, 2001 - 2002
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 1996

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2014 - 2024
  • NJ State Medical License
    NJ State Medical License 2001 - 2015
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Clinical Challenges: When to Add Immunotherapy in Breast Cancer
    Clinical Challenges: When to Add Immunotherapy in Breast CancerOctober 14th, 2021
  • Subcutaneous Fixed-Dose and IV Pertuzumab/Trastuzumab Show Similar Efficacy
    Subcutaneous Fixed-Dose and IV Pertuzumab/Trastuzumab Show Similar EfficacyDecember 13th, 2019
  • SABCS® Daily Highlights for Thursday, December 7
    SABCS® Daily Highlights for Thursday, December 7December 20th, 2023

Hospital Affiliations